Abstract Adipose tissue has a central role in systemic energy balance and the pathogenesis of obesity and its sequelae1,2. In contrast to white adipose tissue, brown adipose tissue (BAT) uses energy to produce heat3. Detectable BAT in humans is associated with decreased prevalence of cardiometabolic diseases4. However, the complete spectrum of health conditions associated with BAT remains unknown, and high-throughput methods to quantify BAT activity in humans are lacking5,6.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Heiko Schöder
Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Illuminating Cardiac Function
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Machine Learning for Automated Interpretation of Fluorodeoxyglucose-Positron Emission Tomography Scans in Lymphoma
2 Interim FDG-PET scans are also used in response-adapted treatment paradigms, particularly for Hodgkin lymphoma.3 For response assessment, residual FDG uptake after treatment is compared with that in normal liver and mediastinal blood pool and graded on a five-point scale2 that defines complete metabolic response as residual FDG uptake in tumor equal to or lower than that of the normal liver reference tissue.
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1
Other Cancers Carlsen et al. from the Righospitalet/Copenhagen University (Copenhagen, Denmark) reported on a “Prospective phase II trial of prognostication by 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT for integrin αvβ3 imaging in patients with neuroendocrine neoplasms (NENs)” [2209].
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups | Journal of Clinical Oncology
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution.
Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis
Highlights • In 38 studies with cancer of unknown primary, 18F-fluoro-2-deoxyglucose positron emission tomography changed management 35%.c. • These were related to find the primary site (22%) or additional metastatic sites (14%). • Similar pooled proportions were seen across subgroups (32.8–38.2%). Abstract Background Cancers of unknown primary (CUP) have traditionally been treated empirically, with a dismal prognosis.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma | Journal of Clinical Oncology
Classical Hodgkin lymphoma (cHL) is often cured with frontline therapy; however, up to 25% of patients with advanced stage and up to 10% with early stage will have relapsed or refractory (rel/ref) disease.1-3 The standard approach for these patients is second-line therapy (SLT) followed by consolidation with high-dose therapy and autologous hematopoietic cell transplant (HDT/AHCT).
First-of-its-kind study links brown fat with broad health benefits
A new study, the largest of its kind ever conducted in humans, has affirmed the link between the presence of brown fat and improved cardiac or metabolic health. The research validates the relatively new hypothesis suggesting the type of adipose tissue commonly referred to as brown fat confers broad health benefits. The body harbors a few different kinds of fat tissue, but the most common is known as white fat.
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
1. Strosberg J El-Haddad G Wolin E et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376: 125-135 2. Kwekkeboom DJ de Herder WW Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-2130 3. Kwekkeboom DJ Kam BL van Essen M et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer.
Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer
Clinical Trial Brief Report Heiko M. Schöder, Paula Demétrio De Souza França, Reiko Nakajima, Eva M Burnazi, Sheryl Roberts, Christian Brand, Milan Grkovski, Audrey Mauguen, Mark PS Dunphy, Ronald Ghossein, Serge K Lyashchenko, Jason S Lewis, Joseph A O'Donoghue, Ian Ganly, Snehal G. Patel, Nancy Y Lee and Thomas Reiner DOI: 10.1158/1078-0432.CCR-19-3484 Abstract Purpose. We performed a first-in-human clinical trial.
Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma
Deborah M Stephens, Hongli Li, Heiko Schöder, David J. Straus, Craig H. Moskowitz, Michael Leblanc, Lisa M Rimsza, Nancy L Bartlett, Andrew M Evens, Ann S. LaCasce, Paul M. Barr, Michael V Knopp, Eric Hsi, John P Leonard, Brad Kahl, Sonali M Smith and Jonathan W Friedberg Blood 2019 :blood.2019000719; doi: https://doi.org/10.1182/blood.2019000719 Key Points Nearly 25% of patients with a negative PET2 relapsed, demonstrating limitations of frontline ABVD and low negative predictive value of PET2.
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer - Sherman - - Cancer - Wiley Online Library
Original Article Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer Eric J. Sherman MD Corresponding Author E-mail address: shermane@mskcc.org https://orcid.org/0000-0002-4960-4783 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medicine, New York, New York Corresponding author: Eric J.
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer
Original Article Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer Eric J. Sherman MD Corresponding Author E-mail address: shermane@mskcc.org https://orcid.org/0000-0002-4960-4783 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medicine, New York, New York Corresponding author: Eric J.
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa M. Rimsza and Jonathan W. Friedberg Blood 2019 133:1762-1765; doi: https://doi.org/10.1182/blood-2018-08-870915 Key Points Elevated posttherapy IL-10 and TARC levels were associated with shorter survival, after adjusting for PET results in S0816.
Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa M. Rimsza and Jonathan W. Friedberg Blood 2019 :blood-2018-08-870915; doi: https://doi.org/10.1182/blood-2018-08-870915 Key points Elevated post-therapy IL10 and TARC levels were associated with shorter survival, after adjusting for PET results in S0816.
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop
1. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018; 175: 313-326 2. Wolchok JD Hoos A O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420 3. Bohnsack O Hoos A Ludajic K Adaptation and modification of the immune related response criteria (IRRC): IrRECIST. Proc Am Soc Clin Oncol. 2014; 32 e22121 4. Seymour L Bogaerts J Perrone A et al.
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
|
By David J. Straus, Michael LeBlanc, Paul Barr Verified, Ariela Noy, James Cook, Randy D Gascoyne, John Leonard, Bruce D. Cheson, Richard Fisher, Heiko Schöder, Craig H. Moskowitz, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Erik S. Mittra, Ann S. LaCasce, Michelle A. Fanale, Michael V. Knopp, Eric D. Hsi, Mary Jo Lechowicz, Brad S. Kahl
|
Journal of Clinical Oncology
Verified
Purpose Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Heiko
Contact Heiko, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack